Tech IPOs, public-market debuts, and what each one means for the exit environment.
SpaceX shares fell further in premarket trading after a Starship test flight was aborted when several engines failed to start, adding a fresh operational setback on top of the stock's already-below-issue-price slide.
Seven companies spanning biotech, fintech, AI and battery materials filed IPO registration paperwork with the SEC within days of each other, a broad-based cluster that extends the sustained widening of 2026's listing pipeline.
Brookfield-backed data center provider Csquare priced its IPO at $21 a share, below its marketed range, and opened down about 3% at $20.90, a soft debut that signals investor caution toward new data-center listings despite AI-driven demand.
Value Add Pulse analysis: the mix of filings landing in mid-July 2026 -- SPAC revival, sustained biotech S-1s, mega-cap AI IPO prep and a wobbling SpaceX debut -- shows a pipeline broadening in kind, not just size.
TRISO fuel maker Standard Nuclear began trading on the NYSE under ticker STDN after slashing its IPO size by 58% to $150 million on the eve of pricing, a live early test of how public markets value pre-revenue nuclear-fuel suppliers.
Data-center operator Csquare priced its IPO $2 below range at $21 a share, raising $1.05 billion, and slipped further on its NYSE debut -- a soft landing for the year's newest bet on AI-driven data-center demand.
SpaceX shares fell below their $135 IPO price for the first time, erasing enough of Elon Musk's paper wealth to end his trillionaire status.
TRISO fuel maker Standard Nuclear cut its IPO to $150 million from a planned $355.88 million on the eve of pricing, a rare down-sizing that signals soft investor demand even inside the hot nuclear-fuel supply-chain theme.
SpaceX stock traded below its $135 IPO price for the first time, a notable early test for one of the most anticipated public listings in recent market history.
Jaguar Health and Vogenx both filed S-1 paperwork with the SEC, adding to a biotech IPO queue that's grown steadily through 2026 as public-market appetite for clinical-stage listings recovers.
Banzai International, FreeCast, authID and Churchill Capital Corp XIII all filed IPO or SPAC-related paperwork with the SEC the same day, a notable cluster in an otherwise quiet software-listing environment.
Anthropic is moving closer to a public listing, with bankers reportedly lining up investor meetings, a step that would make it one of the largest AI IPOs alongside OpenAI's own expected debut.
Stripe's acquisition pace has accelerated meaningfully, with nothing rivaling its reported interest in a roughly $53 billion PayPal-related deal, a scale of ambition unusual for a still-private fintech giant.
Standard Nuclear filed an amended S-1/A refining terms for its planned NYSE listing to fund its small modular reactor buildout, a sign underwriters are finalizing roadshow pricing.
Two SPAC vehicles, Crestone Strategic Capital and Material Resource Acquisition Corp, both progressed toward listing this week, a quiet sign the blank-check market is testing itself again.
Braveheart Bio and Attovia Therapeutics both filed S-1s the same week, adding two names to 2026's biotech IPO pipeline amid the strongest H1 biotech venture funding since 2022.
Anthropic's confidential S-1 and $965 billion valuation sit against a backdrop where this year's actual IPO winners -- SK Hynix, Csquare, Standard Nuclear -- have all been physical infrastructure, not software-first AI labs.
SK Hynix, Csquare, Standard Nuclear and Meta's $50B Louisiana buildout keep winning capital while pure application-layer software IPOs stay scarce -- a gap that's now wide enough to be the real 2026 IPO story.
Plaid is weighing a US IPO after reaching an $8 billion valuation, still well below its 2021 peak of $13.4 billion, a signal of how selectively fintech valuations are recovering as physical AI infrastructure dominates IPO attention.
DeepSeek is reportedly in talks to raise $1.5 billion in private funding as a step toward an eventual IPO, following Goldman Sachs naming it a preferred Chinese AI model.
Legacy data-storage company Quantum Corp filed a new S-1 with the SEC, a notable re-listing move as AI-driven data growth renews demand for storage infrastructure.
SPACs priced 55 IPOs raising $9.8 billion in Q2 2026 alone, and a fresh wave of merger announcements -- from healthcare to energy to biotech -- shows the vehicle finding real footing again after its 2022-era collapse.
Tarsier Pharma's ~$45 million NYSE American debut shows biotech's IPO window remains open in 2026 -- but only for companies with genuinely differentiated, late-stage pipelines, not broad speculative interest.
SK Hynix's 13% first-day pop is the freshest data point ahead of a much bigger test: OpenAI and Anthropic are both racing toward IPOs that could value the two labs at a combined $2 trillion or more.
LimX Dynamics and Unitree are rushing toward IPOs as Chinese humanoid-robotics companies treat a public listing as close to mandatory, following LimX's $200 million pre-IPO round at a $2.21 billion valuation.
Standard Nuclear plans to list on the NYSE this week, offering 18.25 million shares at $18-$21 to raise roughly $356 million at a $3.3 billion valuation, funding its small modular reactor buildout.
Csquare, a data-center operator, is set to list on the NYSE this week offering 50 million shares at $23-$27, targeting roughly $1.25 billion at the midpoint -- one of two infrastructure IPOs headlining this week's calendar.
SK Hynix's ADRs began trading under their permanent ticker SKHY on Monday, days after the memory-chip giant's $26.5 billion Nasdaq debut -- the largest-ever US listing by a non-American company -- popped 13% on its first day.
Value Add Pulse analysis: the largest, best-received 2026 IPOs and pre-IPO windfalls have overwhelmingly gone to the physical and financial infrastructure underneath AI, not to application-layer companies riding on top of it.
James Murdoch's roughly $120 million of pre-IPO SpaceX stock, bought in 2019 and 2020 via Lupa Systems, could now be worth as much as $7.4 billion following SpaceX's public listing, Pitchbook analysis shows.
US IPO proceeds hit roughly $115.6 billion in H1 2026 on a handful of AI and chip mega-deals, but Fortune reports strategists expect H2 to broaden into manufacturing, defense and energy listings.
SK Hynix's ADRs priced at $149 and closed up nearly 13% on their Nasdaq debut, raising $26.5 billion in the largest first-time U.S. listing by a foreign company on record.
SK Hynix priced 177.9 million ADRs at $149 each to raise $26.5 billion on Nasdaq, topping Alibaba's 2014 debut as the largest US listing ever by a foreign company, and popped 14% at the open.
Holtec Nuclear Corp, which owns and is restarting Michigan's 800 MW Palisades plant and leads spent-fuel storage, filed for a Nasdaq listing to fund its SMR-300 small modular reactor rollout.
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.
AI infrastructure company Corvex is going public through a reverse merger with public shell Movano Inc., with Corvex shareholders projected to own about 94.8% of the combined entity.
Healthcare Triangle filed an S-1 registering 28 million shares for resale by Hudson Global Ventures, giving the Nasdaq-listed healthcare-cloud company access to up to $50 million in gross proceeds through an equity line of credit.
Scribe Therapeutics, the CRISPR biotech co-founded by Nobel laureate Jennifer Doudna, amended its S-1 to list on Nasdaq under ticker SCTX, backed by more than $180 million in Sanofi and Eli Lilly partnership payments.
Laser Photonics Corp, a Nasdaq-listed industrial laser-cleaning maker, filed its third S-1 of 2026 on July 10, continuing a pattern of registering shares tied to inducement and placement-agent warrants.
Decoy Therapeutics filed its second S-1 in a month tied to a private placement that could deliver up to $21 million in milestone-based warrant proceeds contingent on trial results and shareholder approval.
iPower Inc, a Rancho Cucamonga-based consumer products company trading under "IPW," filed a new Form S-1 on July 10, its second such registration of 2026 after an earlier S-1/A in January.
Avalanche Treasury Corp, whose AVAT stock has fallen 73% since its Nasdaq debut via SPAC merger, filed a new S-1 as it flags crypto losses and warns it may not survive without additional financing.
Universal Safety Products filed a Form S-1 for up to 10.6 million shares on the same day it warned of a substantial sales and gross-profit decline and an expected net loss for the year ended March 31, 2026.
NeuroSpectrum Insights, formerly Autism Diagnostic Technologies, filed its fifth S-1/A amendment since January, the latest step in a lengthy SEC review process for its planned public offering.
Chinese chipmaker Nexchip Semiconductor priced its Hong Kong listing at HK$32.30 per share, the top of its range, raising roughly HK$6.98 billion ($890 million) as it pursues a dual Shanghai-Hong Kong listing amid a booming HK IPO market.
GridAI Technologies, formerly biopharma company Entero Therapeutics, filed an amended S-1 registering shares tied to recent PIPE financings as it repositions around energy-orchestration and grid-optimization software for AI datacenters.
Zapata Quantum filed an amended S-1/A registering 56.8 million shares for resale, disclosing ongoing losses and going-concern risk despite a recent $15 million Series D and a return to current SEC reporting status.
Nevada-incorporated Mitesco filed an S-1 to register shares issuable under a new equity line of credit, part of a small-cap financing pattern distinct from this week's AI mega-rounds.
BOA Acquisition Corp II filed to raise up to $200 million in a blank-check IPO targeting real estate and infrastructure, part of a steady 2026 revival in SPAC issuance running well below the AI-mega-deal headlines.
European startups raised $24 billion in Q2 2026, up two-thirds year-over-year, with UK startups alone pulling in more than $10 billion -- the region's third-largest quarter on record.
AEON Biopharma filed a fresh S-1 for a biosimilar program while Mobix Labs amended its filing disclosing a going-concern warning -- a reminder this week's IPO pipeline is mostly small-cap, not AI infrastructure.
Smith Micro Software filed a Form S-1 solely to register the resale of shares underlying previously issued warrants and convertible notes, explicitly stating the filing dilutes no existing shareholders.
Beyond SK Hynix's $28-29 billion Nasdaq debut, this week's US IPO calendar is nearly empty -- a sharp contrast to June's run of SpaceX, Cerebras and Lime, and a sign the pipeline is thinner than headline enthusiasm suggests.
SK Hynix priced its Nasdaq ADS offering at roughly $158 per share on July 9 after a book that was reportedly oversubscribed 7 times, with trading set to begin July 10 under ticker SKHY.
European startups exited $7.2 billion across 172 M&A deals in Q2 2026, with four of the 18 global $1 billion-plus VC-backed acquisitions coming from Europe -- while the region's IPO pipeline stays thin.
Anthropic's $50 billion Series H, split across a ten-investor syndicate plus separate multi-billion tranches from Google and Amazon, shows how mega private rounds are absorbing capital that once would have pushed companies toward an IPO.
A wave of small blank-check filings -- Southern Cross Acquisition II, OceanLight Acquisition and others -- is moving through the SEC this week, even as the large-cap IPO calendar stays nearly empty outside SK Hynix's Nasdaq debut.
Leef Brands, a Vancouver-based cannabis company, filed an S-1 registering more than 81.5 million common shares, joining a wave of smaller companies moving through the SEC pipeline this week.
Wyoming-incorporated Jaovi Inc, based in Costa Rica, filed an S-1 registering 4 million shares at $0.03 each for a total offering of just $120,000 -- illustrating the far end of the small-cap IPO pipeline.
2026's IPO market is really two separate markets: trillion-dollar AI infrastructure debuts stacked against a shakier field of traditional listings -- and only one of those two is actually working.
